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In the area of Quality-by-Design (QbD), the determination of process parameters or quality 
attributes of a product using sufficient process analytical technology (PAT) is a crucial for the 
establishment of continuous processes as a standard pharmaceutical technology, such as hot-melt 
extrusion.  For the purpose of the study, three different formulations were developed and design 
space was evaluated with the aid of PAT, while a design of experiment (DoE) was implemented 
to assess the effect of the process critical parameters and to identify the critical quality attributes 
(CQA) of the extrusion processing.  
Solid self-emulsifying drug delivery systems were developed instead of a conventional liquid 
system. Solid surfactants was chosen to emulsify lipids with different HLB properties. Type of 
surfactant, type of lipid, Lipid/surfactant L/S ratio, feed rate, screw speed and screw configuration, 
were the formulation and process parameters evaluated. Solid self-emulsifying drug delivery 
systems were successfully developed on the hot-melt extruder for the first time which is a 
continuous processing technology. 
Blends of theophylline, (HMPC K4M, Affinisol  100LV) were processed using a twin screw 
extruder to investigate the effect of temperature and screw configuration on the various granule 
properties. Particle size distribution was measured using Parsum probe in-line particle size 
analysis. The effect of the critical process parameters to optimize the conditions or design space 
to achieve the tablet with greater sustained release properties. Affinisol 100LV was proven to have 
better sustained release properties and was robust with respect to the change in process parameters.  
Continuous salt preparation was achieved of a poorly water soluble compound Indomethacin with 
a highly water soluble co-former tromethamine. Design of experiments was used to evaluate the 
effect of feed rate, screw speed, temperature on the salt properties. The effect of the different 
process parameters on the extent of formation of the crystalline salt was determined using in-line 
FTNIR analysis. Furthermore, the integration of the DoE experiments demonstrated that 


temperature and screw configuration, had a significant effect on the quality attributes. This QbD 
approach was successfully employed as a paradigm for the development of pharmaceutical 
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I. CHAPTER  
 
INTRODUCTION 
With the advent of combinatorial chemistry and high-throughput screening, the drug discovery 
pipelines have witnessed extremely insoluble molecules (Lee et al., 2017). This results in low 
dissolution rate and variations in the bioavailability when administered orally. Many formulation 
technologies such as salt formation, cocrystallization, lipid based delivery, solid dispersion, 
particle size reduction, have been used to enhance dissolution rate and oral bioavailability of such 
compounds. However, there are limitations associated with respect to each of the methods. For 
example in lipid based drug delivery system, there is critical balance required to be achieved to 
attain complete drug solubility in formulation as well as maintain the drug in solubilized state 
during dilution while dissolution in gastro-intestinal tract. Also there is a need for more reliable 
rapid characterization techniques to enable early phase screening. In addition, the amount of drug 
delivered in lipid based drug delivery system is limited by the solubility of the drug in that lipid, 
surfactant system. With respect to salt or co-crystal formulations there is a tendency for the 
individual components to be dissociated into their counter-parts  (Nie et al., 2016; Qiao, Wang, 
Schlindwein, Davies, & Li, 2013). Amorphous solid dispersion has been of increasing importance 
in the recent years. For early development, formulation of amorphous solid dispersion is performed 
using spray drying, this results in requirement of large quantity of organic solvent for dissolution 
of drug and carrier. The need for solvent handling during manufacturing is increased for such 
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applications. Drug precipitation due to instability and re-crystallization from the polymer matrix 
is a major hurdle in the development of stable amorphous solid dispersions. (Serajuddin, 1999). 
In addition to the techniques mentioned above, salt formation of acidic and basic drugs is most 
common strategy for enhancement of dissolution and widely used in the pharmaceutical industry. 
Salt formation is the primary method used to enhance the dissolution rate and oral bioavailability. 
When salt formation is not a feasible or does not provide desired solubility then other techniques 
for bioavailability enhancement are applied. Approximately, 50% of marketed drugs are 
formulated as salt forms of ionizable active pharmaceutical ingredients (APIs) having acidic or 
basic moieties (Berge, Bighley, & Monkhouse, 1977; Pudipeddi, Serajuddin, Grant, & Stahl, 
2002). 
There has also been an interest in forming Formulation of cocrystals of APIs, has also gained 
significant attention in the past decade, especially when the salt formation is not feasible. However, 
cocrystals do not form for most APIs. As salts could be considered as new APIs and thus have the 
advantage of patent protection, hence are considered more valuable than cocrystals in development 
of pharmaceuticals (Rajput, 2014; Stephenson, Aburub, & Woods, 2011). 
In this study, the limitations of the formulations such as self-emulsifying drug delivery system, 
sustained release tablets, salt formation by solvent driven process has been addressed. Firstly, 
Attempts were made to develop a solid self-emulsifying drug delivery system which eliminates 
the issues of a liquid in capsule type of a system. Secondly, with the sustained release tablet 
formulations, it was proposed to develop a high drug load of melt granules which aids in suitable 
lowering of tablet weight and provide sustained release for upto 18 hours. In addition, salt 
formation of a poorly water soluble API was carried out in a continuous processing technique. All 
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the formulations were developed on a twin screw extruder which eliminates the need of using 
organic solvent for processing.  
In the current research, Quality by design (QbD) and the elements of QbD are applied and its 
implementation in pharmaceutics field is highlighed, including design of experiment, and process 
analytical technology (PAT), are introduced for development of three different formulations. 
Moreover, applications of QbD in various pharmaceutical related unit operations are summarized 
and presented. A quality-by-design (QbD) approach was used to optimize the development of three 
different formulations such as solid self-emulsifying drug delivery system, sustained-release tablet 
and in-situ salt formation of poorly water soluble API manufactured by hot-melt extrusion (HME). 
For the purpose of the study, off-line FTIR chemical imaging, in-line particle size analysis, in-line 
near-infrared (NIR) spectroscopy as a process analytical technology (PAT) was explored while a 
design of experiment (DoE) was implemented to assess the effect of the process critical parameters 







II. CHAPTER  
Applying design of experiments for investigating the impact of formulation and processing 





Lipid-based formulations (LBF) have emerged as a useful formulation strategy to increase the 
bioavailability of poorly water soluble drugs. Around 40% of new chemical entities present 
solubility and bioavailability-related problems. 
Unfortunately development of lipid-based products has been slow, which is probably due to the 
perceived problems of physical and chemical instability, as well as unpredictable bioavailability 
and in vivo performance of these dosage forms. 
Literature presents techniques like solid dispersion, surface modification, cyclodextrin 
complexation,and micellar solutions that have been developed to improve aqueous solubility of 
poorly water-soluble drugs. One such technique used to improve the dispersion and enhance 
solubility of lipophilic drugs is nano-emulsification (Saxena & Hussain, 2012). Nano-emulsions 
(NEs) are clear, stable, isotropic mixtures of oil, water, surfactants and co surfactants. NEs provide 
wide application in the area of drug delivery. Nanoemulsion have gained importance as a platform 
technology is because of their high solubilization capacity for various drugs, nanosize, PGP 
inhibitory effects, stability over wide range of pH and ionic media 
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(Gupta, Hwang, Doshi, & Mitragotri, 2013; Sha, Yan, Wu, Li, & Fang, 2005). This results in 
reproducible plasma concentration profiles and improved bioavailability of various drugs. 
Delivering the NE in the form of pre-concentrates or self-nanoemulsifying drug delivery systems 
(SNEDDS) in hard or soft gelatin capsules is the traditional approach. There is a tendency for the 
surfactants, co-surfactants and oils present in the NE system to interact with the capsule shell and 
affect its integrity (Kim, Kang, Oh, Yong, & Choi, 2012). Hence formulation of emulsions as free 
flowing powders or granules is a better approach. These dry powders can be processed by solvent 
evaporation, spray drying and lyophilization. However, the disadvantage with these process is that 
they are batch processes and involve use of organic solvents. When administered orally these dry 
emulsion powders or solid emulsions will get converted back to the emulsions in gastric fluid. 
Solid nano-emulsions (SMEs) can be formulated by adsorption of SNEDDS on one or more 
carriers (Gumaste et al., 2013).  Solid carrier provides the surface area for adsorption of the oil and 
surfactant droplets and also contributes the bulk to the SMEs. Due to the advantage of solid 
SMEDDS ability to be blended with excipients or converted into tablets, pellets and filled in 
capsules they are preferred choice (Balakrishnan et al., 2009; Bari, Doijad, More, & Disouza, 
2011). The rational design of lipid formulations requires a better understanding of formulation and 
manufacturing variables that may affect the quality of the products. Meeting specific objectives of 
the product and process performance characteristics have to be designed scientifically and not 
merely empirically derived from performance of test batches. The rational co-incides with the 
‘quality-by-design’ principle that has been promoted by the FDA. Ideally, from the selection of 
drug substance, polymorphic form, and excipients, to the design, manufacturing and controls of 
the produc, the approaches can be applied to all phases of pharmaceutical development. 
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This research work has focused on evaluating the feasibility of formulating solid SNEDDS using 
hot melt extrusion technology and focus on the details of the formulation and manufacturing 
variables of solid self-nanoemulsifying drug delivery system (Bahloul, Lassoued, & Sfar, 2014). 
Previous research has demonstrated the use of conventional formulation techniques of SNEDDS 
which has inherent shortcomings such as batch size manufacturing, non-uniformity of content, 
liquid form of SNEDDS, stability, leakage from capsule shell (Dixit & Nagarsenker, 2010) (Cole, 
Cadé, & Benameur, 2008). The present work has addressed these challenges by careful selection 
of solid surfactants which act as the emulsifier as well as solid carrier thereby negating additional 
burden of polymer as carrier. Also a systematic study (response surface model) has been designed 




Fenofibrate was purchased from Ria International (East Hanover, NJ, USA) chemicals and was 
used as model BCS class II drug. Different lipids and surfactants such as Labrafac®PG, Capryo®90, 
Labrasol®, Gellucire®44/14 were generously gifted by Gattefosse (USA) and Lutrol®F68, 
Lutrol®F127, Kolliphor®TPGS by BASF chemicals (New Jersey, USA). HPLC-grade organic 
solvents such as methanol was obtained from Fisher Scientific (USA). 
3. Methods 
 
3.1 Screening of lipids and surfactants 
3.1.1 Solubility of fenofibrate in lipid and surfactant 
Lipids were selected from different chemical class with wide range of HLB values (Figure 1,2). 
Excess fenofibrate was weighed and added to 5ml of lipids and 500mg surfactants. Solubility 
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studies were conducted by placing an excess amount of fenofibrate in scintillation vials containing 
approximately 5–7 g of vehicles independently. The mixture was then shaken in a water bath at 
25°C for 24 h. The shaking time of 24 h was set because preliminary experiments showed that the 
solutions reached equilibrium within 12 h and there was no further change in concentration when 
shaking was continued for 24 h and longer. The supernatant was withdrawn, filtered through 0.45-
μm polypropylene membrane filter and diluted with acetonitrile for HPLC analysis. A Waters High 
performance liquid chromatography (HPLC) system equipped with a Water 600 binary pump, 
Waters 2489 UV/detector, and Waters 717 plus auto-sampler (Waters Technologies Corporation, 
Milford, USA) and a Phenomenex Luna 5um C18 (2) 250 x 4.6 mm column (Torrance, CA, USA) 
were used at a detection wavelength of 288 nm. The mobile phase consisted of acetonitrile and 
water at a ratio of 80:20% (v/v). The mobile phase flow rate was maintained at 1.0mL/min. and an 
injection volume of was 10 μL was used HPLC data was analyzed using Empower V. software 
(Milford, MA, USA)(Patel, Li, & Serajuddin, 2016; Shah & Serajuddin, 2012).  
 
Labrafil®M1944 (HLB 9) Oleoyl polyoxyl-6-glycerides 
 




Labrasol® (HLB 12) Caprylocaproyl polyoxyl-8-glycerides 
 
Labrafac®PG (HLB 1) Propylene glycol dicaprylate 
Figure 1: Structure of Lipids used in the formulations 
 
Surfactant name Surfactant chemical name HLB 
Lutrol F68 Poloxamer 188 
Polyoxyethylene-polyoxypropylene block 
copolymer (Ratio 80:27) 
24 
Lutrol F127 Poloxamer 407 
Polyoxyethylene-polyoxypropylene block 
copolymer (Ratio 101:56) 
18 
Gellucire®44/14 Lauroyl polyoxyl-32 glycerides 11 
Kolliphor®TPGS (D-α- Tocopherol polyethylene glycol) 13 
 
Figure 2: Surfactants used in the formulation 
3.1.2 Dispersion study  
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Solid SNEDDS were evaluated for their ability to disperse into globules of size <200nm in suitable 
dissolution medium. Labrafac®PG (HLB 1) and Capryol®90(HLB 5) were chosen as the lipids due 
to higher solubility of fenofibrate in the lipids and Lutrol F68 and Lutrol F127 were selected as 
the solid surfactant system. Fenofibrate was loaded in the lipids upto 90% of its solubility in order 
to avoid precipitation due to saturation. Two different lipid:surfactant ratios were chosen of 50:50 
and 60:40 to test the dispersion efficiency in Fasted state Simulated Gastric Fluid (FaSSGF). 
4.1.3 In-vitro dissolution 
The in-vitro dissolution of the both the ratios formulated with the lipids and surfactants were 
evaluated using USP type II apparatus in 250ml of simulated FaSSGF at 37°C. The formulations 
were incorporated into a dialysis bag and placing 5ml of media into the dialysis unit and clipped 
using dialysis bag sealer. Samples were withdrawn at 5, 15, 30, 60, 120mins. 
3.2 Feasibility of preparation of solid SNEDDS 
3.2.1 Preparation of solid SNEDDS by conventional technique- Melt sonication 
Fenofibrate loaded solid SNEDDS were prepared conventionally by melt probe sonication 
technique. Liquid lipid such as Labrafac®PG, Capryol®90 were chosen as the desired lipid for the 
formulation. Two different solid surfactant such as Lutrol®F68 and Lutrol®F127 were selected for 
the formulation. Fenofibrate was pre-dissolved in the lipid upto 90% its solubility. The lipid and 
solid surfactant were mixed in different ratios of 50:50 and 60:40 respectively as shown in table 2 
and 3. The drug loaded lipid solution was mixed with the solid surfactant and heated upto 70°C so 
that solid surfactants were completed melted. At this temperature the mixture was sonicated on an 
Ultrasonicator for 5mins.  
3.2.2 Preparation of modified Labrafac®PG Solid SNEDDS  
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The previous mentioned formulation of Labrafac®PG formulation was modified where 50% of the 
total incorporated solid surfactant was replaced with Kolliphor®TPGS and Gellucire®44/14 as co-
surfactants (Table 4).  
3.2.3 Preparation of solid SNEDDS by hot melt extrusion  
Solid self nano-emulsifying drug delivery (S-SNEDDS) systems of fenofibrate were formulated 
by twin screw extrusion process using Process 11, Thermo Fisher Scientific®. The solid surfactants 
were fed from the hopper, whereas the lipid was added from third zone of extruder. The extrusion 
was carried out at 100 rpm and 7% feed rate (1.9 g/min) (Table 6). The temperature of extrusion 
process was kept as 65°C (Zone1-4), 45°C (zone 5-6) and 30°C (zone 7-8). Initial temperature of 
operation assured complete melting of the solid surfactants, while gradual cooling towards the end 
was carried to avoid separation of surfactant and lipid matrix once the product exits the extruder. 
Two different screw configurations were evaluated for its effect on obtaining the desired product 
characteristics whose schematic representation is shown in Figure 3 (A) (B).   
3.3 Design of experiments 
A response surface (optimal) design was adopted to study the effect of critical process parameters 
and formulation variables on the product characteristics. Optimal design is one of the most 
commonly used designs of the experiment. They are the resolution five designs, so they can be 
used to study the main effects and interactions between variables to be investigated. The processing 
input variables studied were feed rate (4-8 g/min), screw speed (100- 200 rpm), screw 
configuration (impact of one kneading block v/s two) (Figure 3A and 8B); while the formulation 
variables were Ratio of Lipid to Surfactant (0.5-1 L/S ratio), type of lipid (HLB 5, 9, 12), type of 
surfactant used (HLB 18, 24). A total of 41 experimental trials with a response surface design were 
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constructed using design expert stat-ease software version 9 to study the six variables (Table 1). 
Multilinear regression analysis was performed to test the significance of the model and the factor 
coefficients. The experimental runs (formulations) were prepared in triplicate. The dependent 
variables were In-vitro dissolution (Y1), average particle size (Y3), poly-dispersity index (Y4). 
The linear equation of the model is as follows: 
Y = b0 + b1X1 + b2X2 + b3X3 + b4X4 + b5X5 + bnXn… 












E: Type of 
lipid (L) HLB 
F: Type of 
surfactant (S) 
HLB 
1 5.11 115 0.68 1 5 24 
2 6.02 200 0.85 1 5 24 
3 8.00 100 0.80 1 5 24 
4 5.40 169 0.96 1 5 24 
5 6.61 110 0.50 1 5 18 
6 5.60 166 0.72 1 5 18 
7 8.00 176 0.50 1 9 24 
8 8.00 176 1.00 1 9 24 
9 5.40 100 0.96 1 9 24 
10 5.11 100 0.68 1 9 24 
11 4.00 200 0.50 1 9 18 
12 7.32 145 0.50 1 9 18 
13 7.73 100 0.96 1 9 18 
14 4.00 121 0.50 1 12 24 
15 8.00 200 0.64 1 12 24 
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16 5.60 174 0.72 1 12 24 
17 4.00 156 0.80 1 12 24 
18 6.25 200 0.58 1 12 18 
19 6.02 121 0.85 1 12 24 
20 4.00 165 1.00 1 12 18 
21 8.00 200 0.78 1 12 18 
22 6.00 100 0.95 1 12 18 
23 4.75 183 1.00 2 5 24 
24 8.00 133 1.00 2 5 24 
25 4.00 200 1.00 2 5 18 
26 4.88 100 0.50 2 5 18 
27 6.48 200 0.51 2 5 18 
28 4.00 200 0.50 2 5 18 
29 8.00 183 1.00 2 5 24 
30 7.98 117 0.53 2 9 24 
31 4.00 200 0.50 2 9 24 
32 8.00 154 0.50 2 9 24 
33 4.55 145 1.00 2 9 18 
34 5.51 200 1.00 2 9 18 
35 4.00 145 0.62 2 9 18 
36 8.00 100 0.88 2 9 18 
37 4.22 100 0.50 2 12 24 
38 6.25 198 0.58 2 12 24 
39 7.14 145 0.63 2 12 18 
40 4.00 150 0.79 2 12 18 
41 8.00 100 0.99 2 12 18 





Figure 3 (A): Screw configuration 1 (2kneading blocks), 11mm twin screw extruder Thermo 
Scientific® 




3.4 Characterization of conventional and hot-melt extruded formulations 
The extruded formulations were compared to the conventionally prepared ones by melt sonication 
technique. The S-SNEDDS prepared were analyzed for percent drug dissolved in media by 
Dissolution testing using dialysis bag, physical state of drug in formulation by Differential 
Scanning Calorimetry, Content Uniformity by FTIR Chemical Imaging, Globule size of dispersed 
emulsion.  
3.4.1 Differential Scanning Calorimetry  
DSC studies were performed with a Perkin Elmer Diamond differential scanning calorimeter 
(DSC) equipped with Pyris software (Shelton, CT, USA). Samples were prepared by sealing 3-5 
mg of pure API, physical mixtures, blank formulations, drug loaded extrudates in hermetically 
sealed aluminum pans and heated from the temperature range of 30°C to 100°C at the heating rate 
of 20°C/min under an inert nitrogen atmosphere at a flow rate of 20 mL/min. 
3.4.2 Fourier transforms infrared spectroscopy (FTIR) 
FTIR spectra of the API, lipids, surfactants and milled extrudates were recorded using an Agilent 
Cary 660 FTIR spectrophotometer (Santa Clara, CA, USA) to investigate any possible interactions 
between the drug, polymer and other excipients. The infrared images were produced by taking 
spectral derivatives of the obtained spectra and isolating spectral bands representative of 






3.4.3 Content Uniformity  
In addition to evaluating the content uniformity via chemical imaging, the content of fenofibrate 
in formulation was analyzed by assaying a measured quantity using HPLC reverse phase analysis. 
About 50mg of the formulations were weighed and dissolved in methanol to dissolve the API. The 
extracted methanolic solution was suitably diluted to be analyzed via reverse phase HPLC. The 
content uniformity was evaluated using Waters HPLC-UV system (Water Corporation) and a Luna 
5μm C18 column at 285nm.  
Content Uniformity ratio = Actual drug loading/ Expected drug loading. 
When the content uniformity ratio was close to 1 implied that the actual and expected drug loading 
was similar. When content uniformity ratio was >1 it implied that the actual drug loading was 
higher than expected, whereas when it was <1 it implied that the actual drug loading was lesser 
than expected. 
3.4.4 Dispersion testing and globule size analysis 
To simulate the degree and efficiency of emulsification of lipids in GI fluids after oral 
administration of the solid systems developed, the dispersion test was conducted by using the USP 
apparatus II (paddle method; Distek Inc., NJ, USA) at 50 RPM and 37°C with 250 ml of simulated 
FaSSGF as the dispersion medium. Since the aqueous solubility of the drug fenofibrate was pH-
independent and all lipids and solid systems were non-ionic, the medium did not affect the release 
of the drug. Since the solid dosage form after oral administration encounters an acidic environment 
in the stomach FaSSGF was chosen as the medium.  
A volume of 250 ml was selected for the dispersion test to mimic the gastric fluid volume as per 
the Biopharmaceutical Classification System after oral administration of solid dosage unit. 
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Approximately 200mg of the formulation was directly added to the dispersion vessel using 
weighing boats. To evaluate the effect of drug loading, if any, on emulsification properties of solid 
systems, controls without drugs were also subjected to dispersion test. Thus, the dispersion test for 
a particular formulation was conducted six times, three with drug and three without drug. Both 
drug concentration and particle size of dispersion fluids were analyzed for formulations with drugs, 
while only particle sizes of oil globules were measured for drug-free systems. Aliquots from 
dispersion vessels were withdrawn at 5, 15, 30, 45, 60, 90, 120 min time points. Particle sizes were 
measured without any dilution. The mean particle size and polydispersity index (PDI) of the 
developed solid SNEDDS were determined by using Zetasizer Nano ZS (Malvern, USA). 
Dynamic light scattering technique was used to measure particle size. This technique measures the 
diffusion of particles moving under Brownian motion and converts this to size and a size 
distribution using the Stokes-Einstein relationship.  
3.4.5 In-vitro dissolution 
All the formulations (conventional and hot-melt extruded) were evaluated for the in-vitro drug 
dissolution profile. 100mg of formulation was weighed and filled into dialysis bag (MWCO 
100,000 daltons, pore size 4nm). About 5ml of dissolution medium was added to the dialysis bag. 
The dialysis bag was placed in the dissolution medium containing FaSSGF. The dissolution testing 
was performed using type II dissolution apparatus. The use of dialysis method ensured that only 
fenofibrate solubilizing in the gastric fluid was analyzed and not the lipid micelle globules. The 
samples were taken at different time intervals of 5, 15, 30, 60, 120mins and analyzed for 




4. Results and Discussion 
 
4.1 Screening study to evaluate SNEDDS formation 
4.1.1 Dispersion study  
Solid SNEDDS were evaluated for their ability to disperse into globules of size <200nm. Labrafac® 
PG (HLB 1) and Capryol®90(HLB 5) were chosen as the lipids due to higher solubility of 
fenofibrate in the lipids (Table 2) and Lutrol®F68 and Lutrol®F127 were selected as the solid 
surfactant system. Fenofibrate was loaded in the lipids upto 90% of its solubility in order to avoid 
precipitation due to saturation. Two different lipid: surfactant ratios were chosen (50:50 and 60:40) 
to test the dispersion efficiency.  
Lipid and surfactant HLB Solubility (mg/ml) 
Capryol®90 5 112.93 
Labrafac®PG 1 94.34 
Labrafil®M1944 9 57.2 
Labrasol®                                                    12 92.01
Lutrol ®F68 24       
      < 50 µg/ml Lutrol ®F127 18 
Kolliphor® TPGS 13 
Gellucire® 44/14 11 
Table 2: Solubility data for fenofibrate in different lipids 
All the evaluated ratios of the different lipid and surfactant (conventional) formulations were found 
to have particle size of <200nm. From Table 3, 4 it can be seen that Capryol®90 has particle size 
lesser than Labrafac®PG. Labrafac®PG has greater hydrophobic groups as compared to Capryol® 
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90, hence stabilizing the lipid micelle is a challenge. Due to this, certain co-surfactants such as 
Kolliphor®TPGS and Gellucire®44/14 with lower HLB compared to the existing Lutrol® 
surfactants. were added at a concentration of 50% of the initial surfactant which is depicted in 
Table 5. As seen in figure 4 the particle size of modified Labrafac®PG solid SNEDDS dispersed 
in the gastro intestinal fluids displayed smaller globule size than the original solid SNEDDS 
formulation. This can possibly be due to stabilization of the globule with additional hydrophobic 
chains of the co-surfactant. Kolliphor®TPGS provided the better stability to the formulation as 
compared to Gellucire®44/14.   
Formulation Lipid 
 
Surfactant (Ratio of lipid: 
surfactant) 
Average particle size (nm) 
L-1 Labrafac®PG Lutrol® F68 (50:50) 150 
L-2 Labrafac®PG Lutrol® F68 (60:40) 161 
L-3 Labrafac®PG Lutrol® F127 (50:50) 186 
L-4 Labrafac®PG Lutrol® F127 (60:40) 174 
 
Table 3: Dispersion test and particle size measurement of conventionally prepared SNEDDS of 
Capryol® 90 
 




C-1 Capryol®90 Lutrol® F68 (50:50) 108 
C-2 Capryol®90 Lutrol® F68 (60:40) 102 
C-3 Capryol®90 Lutrol® F127 (50:50) 147 
C-4 Capryol®90 Lutrol® F127 (60:40) 118 
 




Formulation  Lipid (50%) Co-Surfactant (25%) Surfactant (25%) 
SNEDDS-1 Labrafac®PG Kolliphor®TPGS Lutrol®F68 
SNEDDS-2 Labrafac®PG Gellucire®44/14 Lutrol®F68 
 




SNEDDS- 1 HME- 1 
SNEDDS- 2 HME- 2 
C1 HME- 3 
C2 HME- 4 
C3 HME- 5 
C4 HME- 6 
 
Table 6: Conventional formulation and their respective hot-melt extruded formulation denotation  
The particle size of hot-melt extruded modified Labrafac®PG formulations (Figure 5) compared 
to the conventional formulations was significantly lesser due to increased shear intensive mixing 
that could be achieved during extrusion and better molecular miscibility between the solid 
surfactants, co-surfactants and lipids. Also better content uniformity of the hot melt extruded 
formulations was one of the reasons. This was also shown with respect to Capryol®90 solid 




Figure 4: Particle size of modified Labrafac®PG SNEDDS (conventional method) 
 





















































Figure 6: Particle size of Capryol®90 SNEDDS dispersed formulations (hot –melt extruded) 
 
4.1.2 In-vitro dissolution 
In-vitro dissolution of Labrafac®PG SNEDDS formulation (Figure 7), did not result in complete 
dissolution of API into the FaSSGF medium. All the ratios of 50:50 and 60:40 only resulted in the 
25-35% drug dissolved at the end of 2 hours. Due to larger particle size of the Labrafac®PG 
globules, the total specific surface area available was smaller. Hence, the formulation was 
modified to incorporate co-surfactants to decrease the globule size and hence increase the area 





























Figure 7: In-vitro dissolution test for Labrafac®PG SNEDDS (conventional method)  
From the plot of %in-vitro dissolution of modified Labrafac®PG, it was seen that the release 
increased upto 45% for Gellucire®44/14 formulations and 68% for Kolliphor® TPGS at the end of 
2 hours. Inspite of the change in formulation composition, significant increase in dissolution was 
not achieved with conventional melt sonicated solid SNEDDS formulations (Figure 8). 
 



































































 The hot-melt extruded formulations achieved significantly higher drug release (65% and 85%) as 
compared to the conventional ones as noted from Figure 9. Although Labrafac®PG extruded 
formulations attained greater release as compared to conventional ones, complete 100% release 
was not attained. This can be due to higher affinity of drug for the hydrophobic lipid and poor 
release from the lipid into the dissolution medium.  
 
Figure 9: In-vitro dissolution test for modified Labrafac®PG SNEDDS (hot-melt extrusion 
method) 
Hence, Capryol®90 a lipid with higher hydrophilicity (HLB) was chosen for the formulation. From 
Figure 10, it can be seen that greater than 85% drug release was obtained in the first 15min of the 



































Figure 10: In-vitro dissolution test for modified Capryol®90 SNEDDS (hot-melt extrusion method) 
4.1.3 Differential Scanning Calorimetry 
The physical state of fenofibrate in the formulation was evaluated using a differential scanning 
calorimeter (Pyris®DSC) to evaluate re-crystallization. Figure 11 (A), (B), (C) demonstrates the 
Differential Scanning thermograms of physical mixture of formulation components; blank and 
fenofibrate loaded hot-melt extruded formulations. Fenofibrate has a melting point of 87°C and 
the solid surfactants used in the formulations melt between 45-55°C. It could be inferred that 
fenofibrate was in amorphous or solubilized state in the hot melt extruded formulations. From 

































Figure 11 (A): DSC thermograms of physical mixtures of fenofibrate, lipid and surfactant 
 











Figure 11 (C): DSC thermograms of hot-melt extruded fenofibrate loaded formulations 
4.1.4 Fourier Transform Infra-red Spectroscopy and Imaging 
Figure 12 shows the FTIR spectra’s of pure components incorporated into the modified Labrafac® 
PG formulations. At a wavenumber (1650 cm-1) corresponding to only fenofibrate complete 3D 
imaging was performed to evaluate content uniformity of the drug in conventional and hot-melt 
extruded formulations. From Figure 13 (A) (B) corresponding to SNEDDS-1 and SNEDDS-2 
(conventional) it can be seen that the distribution was very non-uniform where high concentrations 
of drug (red area) was seen at the edges of the sample as opposed to Figure 14 (A) (B) 
corresponding to HME-1 and HME-2. In the latter case fenofibrate was seen uniformly distributed 
throughout the sample specimen. Uniform distribution of the API can be attributed to homogenous 
distribution of lipid inside the solid surfactant matrix, as the drug has solubility only in the lipid 
and negligible solubility if the surfactant. During the second half of the hot-melt extrusion process 
where the temperature was gradually reduced below the melting temperature of the solid 
27 
 
surfactants, solidification was observed. During this solidification, homogenous blending between 
lipid and surfactant was provided by the kneading blocks of the extruder, which was not available 
in the conventional method. In the conventional method, as the formulation cooled, there was 
separation due to solidification of surfactant. 
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(A) SNEDDS-1                                                  (B) SNEDDS-2 
Figure 13: FTIR Chemical Images of modified Labrafac®PG SNEDDS (conventional) 
     
                  (A) HME-1                                                  (B) HME-2 





4.2 Evaluation of DOE response surface model 
4.2.1 Effect on in-vitro dissolution rate 
The type of lipid and surfactant chosen for formulation significantly impacted the dissolution rate 
of the formulations as shown in Figure 15, 16. Formulations with Lutrol®F68 suggested higher 
dissolution rate compared to those with Lutrol®F127. This can be attributed to higher hydrophilic 
groups in Lutrol®F68 which can efficiently form micelles of a smaller size compared to those with 
Lutrol®F127 and result in greater surface area available for dissolution into the media. All three 
lipids had greater than 85% drug dissolved within 15mins. Relatively Labrafil® M1944 had higher 
dissolution rate compared to both Capryol®90 and Labrasol®. This was possibly due to lower drug 
loading of 1.7-2.5%w/w that could be achieved in Labrafil®M1944 compared to 3.5-5.06%w/w in 
Capryol®90 and 2.7-4.15% w/w in Labrasol®. Hence, there was twice the amount of surfactant 
available for solid SNEDDS formulation in Labrafil®M1944 as compared to those in Capryol®90 
and Labrasol®. The Pareto chart plot for effect of different variables on the in-vitro dissolution is 
shown in figure 15. The type of lipid and surfactant were the two main factors which influenced 
dissolution rate significantly (p<0.05). The interactions between the parameters did not 




Figure 15: Pareto Chart to study the impact of input variables on In-vitro dissolution rate 
 
Figure 16: 3D plot for influence of input variables on In-vitro dissolution rate 
4.2.2 Effect on Content Uniformity 
The type of surfactant significantly impacted the uniformity of distribution of API. Lutrol®F127 
is reported to have higher melt viscosity as compared to Lutrol®F68 (Kocbek, Baumgartner, & 
Kristl, 2006; Schilling & McGinity, 2010; Schmolka, 1977). Hence formulations with Lutrol®F68 
had good content uniformity as compared to those with Lutrol®F127 due to better dispersion effect 
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in the kneading zone. Figure 18 (A) and (B) it can be noted that formulation with screw 
configuration 1 and Lutrol®F68 had the content uniformity ratio approximately 1 and those with 
screw configuration 2 and Lutrol®F68 was significantly greater than 1. This implies that a 
minimum of two kneading blocks (screw configuration 1) was essential in the formulation of 
uniform dispersion of lipid into the surfactant matrix. From the pareto chart (Figure 17) it is noted 
that the type of lipid also significantly impacted the content uniformity. Formulations with 
Capryol®90 and Labrasol® had content uniformity ratio close to 1 (1.002, 1.06) whereas for 
Labrafil®M1944 it was significantly different (0.7).   
 




Figure 18 (A): 3D plot for influence of input variables on content uniformity (Feed rate 4g/min, 
Screw speed 200rpm, L/S ratio 0.60, Screw configuration 1) 
 
Figure 18 (B): 3D plot for influence of input variables on content uniformity (Feed rate 4g/min, 
Screw speed 200rpm, L/S ratio 0.60, Screw configuration 2) 
4.2.3 Effect on Particle size 
The particle size of the globules was significantly impacted by the type of the lipid and screw 
configuration. Formulations manufactured with screw configuration 1 had significantly smaller 
particle size as compared to the ones with screw configuration (Figure 20). The greater the intensity 
of shear incorporated due to screw configuration 1 aided in greater molecular dispersion of the 
surfactant with the lipid and hence resulted in a finer globule size. The pareto chart (Figure 19) 
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indicates the type of lipid to have significant influence on the globule size. The smallest globule 
size was achieved by formulations with Capryol®90.   
 
Figure 19: Pareto Chart to study the impact of input variables on particle size of SNEDDS 
dispersion 
 
Figure 20: 3D plot for influence of input variables on particle size (Feed rate 4g/min, Screw speed 
200rpm, L/S ratio 0.60, Type of surfactant Lutrol®F68) 
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4.2.4 Effect on Poly-dispersity index 
The polydispersity index (PDI) of the dispersed globules of the solid self nano-emulsifying 
systems was significantly impacted by the type of lipid incorporated in the formulation (Figure 
21). The PDI was lower for formulations with Capryol®90 due to its lower HLB value as compared 
to Labrafil®M1944 and Labrasol® (Figure 22). The optimum HLB of Capryol®90 ensured the 
solubility of fenofibrate in the lipid globule and after dispersion in the media ensured gradual 
dissolution of API from the relatively smaller and stable micelle. In case of Labrafil®M1944 and 
Labrasol® lipids, due to their higher HLB, had greater preferred miscibility in water which resulted 
in unstable micellar structure.  
 





Figure 22: 3D plot for influence of input variables on PDI of particles from SNEDDS dispersion 
4.2.5 Desirability index 
The desired or optimum process and formulation parameters were plotted from Design Expert 
software (Figure 23) which resulted in higher value of in-vitro dissolution (Y1), content uniformity 
ratio equivalent to 1 (Y2), lowest possible globule size (Y3) and Lowest poly-dispersity index 
(Y4). The optimum process conditions (desirability of 0.9) were 4g/min feed rate, 200rpm screw 
speed, Screw configuration 1, Lipid/Surfactant (L/S) 0.6, Capryol®90 as the lipid and Lutrol®F68 
as the surfactant to attain >90% in-vitro dissolution, Content Uniformity ratio of 1.02, Particle size 








Hot-melt extrusion was shown as a feasible and preferred process for manufacturing solid 
SNEDDS. Increased residence time of formulation due to low feed rate, higher shearing action 
imparted by the screw configuration and high screw speed was desired to manufacture solid 
SNEDDS with desired product characteristics. Lipid such as Capryol®90 with the appropriate 
balance of hydrophilic and hydrophobic groups was desired to be formulated into solid 






III. CHAPTER  
Impact of formulation and process parameters in twin screw hot-melt granulation coupled 
with in-line particle size analysis of sustained release HPMC granules 
1. Introduction 
 
Twin screw granulation is currently being explored as a continuous manufacturing technology over 
batch type processes such as high shear granulation and fluid bed granulation. Development of 
sustained-release oral formulations over period of 12 h usually requires release-modifying 
polymers at the level of above 50% of the total weight (Vasanthavada et al., 2011). The aim of the 
current investigation was to reduce the use of release modifying polymer content in production of 
melt granules. This was done by focusing on the manufacturing aspects of processes to generate 
desirable quality of product. The processing conditions of the polymers (Affinisol®100LV and 
Methocel®100 LV) were established using hydrophilic (Xylitol) and hydrophobic (stearic acid) 
plasticizing agents. Theophylline was chosen as the model API having high water solubility 
(7.36mg/ml) and high melting point (273°C). Very few reports are available in the literature 
describing screw configuration for hot melt granules. In this study the different screw 
configurations to provide melt granules were systematically investigated (Mu & Thompson, 2012). 
For a continuous processing technology such as twin screw melt granulation, establishing quality 
by design is important to evaluate the impact that the process change has on the granule properties 
such as in-line particle size.   
The Parsum probe IPP80® (Malverrn Instruments) was used to measures particle size distributions 





Figure 24: Schematic of melt granulation process coupled with Parsum Probe IPP80® for granule 
size distribution measurement 
 
 





The probe uses a patented spatial filter technique which as been developed and enhanced by 
Parsum (Figure 29). The Parsum probe contains an array of light-sensitive detectors which are 
illuminated by a laser. This array can detect single particles as they pass through the laser beam 
within the probe measurement zone. The shadow produced by each particle can be used to calculate 
the particle velocity and its chord length (particle size). The probe is capable of measuring the 
particles in the size range of 50µm- 6000 µm. The detector signals are sampled very rapidly, with 
sampling rates reaching several thousand particles per second. This ensures that a realistic number 
of particles is measured, giving confidence that the results reported are representative of the 
material within the process. The results from each particle are collected into a first-infirst-out 
buffer and are used for calculating a particle size distribution. The particle size distribution data is 
continuously updated during operation of the probe, providing a real time particle size trend. This 
provides direct insight into the performance of the process. The technique would present 
significant advantage over the conventional seive analysis which is limited by sampling a limited 
quantity from the entire  extruded granule batch. Hence analysis is dependent on sampling 
technique.  
The purpose of our work is listed in brief below: 
Aim 1: Development of sustained release melt granules with a high drug load of 77%, by melt 
granulation using a twin-screw extruder.  
Aim 2: Investigate the effect of processing temperature and screw configurations on the 
development of sustained-release melt granules.  






Methocel 100LV, Affinisol were received as gift samples from Colorcon (PA, USA), Stearic acid 
xylitol, HPLC solvents and vials were purchased from Fisher Scientific (USA).  
3. Methods 
 
Theophylline granules with high drug loading (77%) were prepared using a twin screw melt 
granulation process in a 16mm (Thermo Scientific® Prism Eurolab) extruder. Design Expert® was 
used to develop a response surface model (p< 0.05) and evaluate the effects of both processing and 
formulation variables of HPMC grades. Affinisol® 100LV and Methocel®100 LV (HPMC 100LV) 
having a tg of 130°C and 180°C, respectively, were employed as release modifying polymers. 














Role of ingredient  Name  Concentration %        
Amount     
(mg) 
F1 Granules 
API Theophylline 77 
  Release modifying 
polymer 
Affinisol ®100LV 23 
F2 Granules 
API       Theophylline                        77 
  
Release modifying 
polymer            
Methocel® 100LV 20.7 
Melt binder Stearic acid 2.3 
F3 Granules 
API       Theophylline                        77 
  
Release modifying 
polymer            
Methocel® 100LV 20.7 
Melt binder Xylitol 2.3 
Tablets 
Granules     F1/F2/F3 granules 70 175 
Lubricant  




Microcrystalline      
cellulose 
29 72.5 
Total 100 250 
 
Table 7: Details of granule and tablet formulation 
 
Three different screw configurations (SC) were used to study the impact of the number of kneading 
blocks and the presence of distributive mixing elements (DME) on the particle size distribution 
(PSD) of granules; where SC1 (2 kneading blocks), SC2 (2 kneading blocks + 1 DME) and SC3 




Figure 26: Schematic representation of different screw configurations 16mm Prism Eurolab® 
twin screw extruder Thermo Scientific® 
 
 DSC analysis was performed to screen stearic acid and xylitol as plasticizers to process 
Methocel®100LV. Affinisol®100LV a highly substituted form of HPMC 100LV and manufactured 
to reduce the operating extrusion temperature. Theophylline (77% w/w) was blended with 
Affinisol®100LV or Methocel®100LV with melt binders as shown in Table 7 using a V-shell 
blender (Globe- Pharma, Maxi blend™ New Brunswick, NJ) for 20 min at 25 rpm, after passing 
through US# 35 mesh screen to remove any aggregates that may have formed.  Response surface 
design (optimal) was used for generating the design points (Table 8) and Design Expert software 
was used for analyzing the data. Thus, the three different variables studied were temperature of 
extrusion, screw configuration, Formulation (Affinisol®100LV/Methocel®100LV with 10% 
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stearic acid/ Methocel®100LV with 10% xylitol as release modifying polymer). The obtained 
granules were milled using a Fitz mill sieve size 40 at 4000rpm. Extra-granular excipients such as 
magnesium stearate (1%) and Microcrystalline cellulose were added to the milled granules and 
blended using a V-blender for 10mins. This blend was then compressed into tablets of 250mg 
using a 10mm circular die and punch on a single station tablet press (tablet drug loading 70%). 
Run 
no. 
Factor 1 Factor 2 Factor 3 
A:Temperature B: Screw 
configuration 
C: Formulation 
1 1 1 Affinisol® 100LV 
2 -1 1 Methocel 100 LV ® 10% Xylitol 
3 -1 2 Methocel 100 LV ® 10% Xylitol 
4 -1 1 Methocel 100 LV ® 10% Stearic acid 
5 1 2 Affinisol® 100LV 
6 1 2 Methocel 100 LV ® 10% Stearic acid 
7 1 2 Methocel 100 LV ® 10% Xylitol 
8 -1 3 Methocel 100 LV ® 10% Xylitol 
9 1 3 Methocel 100 LV ® 10% Stearic acid 
10 -1 1 Affinisol® 100LV 
11 1 3 Methocel 100 LV ® 10% Xylitol 
12 1 3 Affinisol® 100LV 
13 -1 3 Affinisol® 100LV 
14 -1 2 Affinisol® 100LV 
15 -1 3 Methocel 100 LV ® 10% Stearic acid 
16 -1 2 Methocel 100 LV ® 10% Stearic acid 
17 1 1 Methocel 100 LV ® 10% Stearic acid 
18 1 1 Methocel 100 LV ® 10% Xylitol 
 








3.1 Granule and tablet Characterization 
3.1.1 Differential Scanning Calorimetry 
Pre-formulation evaluation was performed using Differential Scanning calorimetry (TA DSC25) 
testing of physical blend of 10% stearic acid and 10% xylitol with Methocel®100LV. About 5-
8mg of samples were weighed into aluminum T-zero® pans and heat cycle was run from 30°C-
200°C at a rate of 20°C/min. The glass transition temperature of these physical blends was 
calculated using Trios 4.2.1 software. 
 
3.1.2 Milled granule flowability 
The granules were characterized for flowability, strength, in-line particle size, and surface 
morphology.  
Carr’s index and Hausner’s ratio were calculated to estimate the flowability of the granules. Bulk 
density was calculated by measuring the volume of 5 g granules in a 10 ml graduated cylinder. 
The cylinder was tapped 100 times until no further reduction in the volume of the granules was 
observed. Tapped density was calculated using the volume of the granules after tapping (Patil, 
Tiwari, Upadhye, Vladyka, & Repka, 2015).  
Carr’s Index = Tap density – Bulk density/ Tap density X 100 





3.1.3 Scanning Electron Microscopy 
The intact granules were evaluated for their surface texture using Scanning Electron microscopy. 
The surface morphology was investigated using a JEOL 6300F scanning 
electron microscope (JEOL, Tokyo, Japan) operated at 5 keV. The samples were mounted on an 
aluminum board using a double-sided adhesive tape and sputter coated with gold using a sputter 
coater. A scanning electron microscope operated at various magnifications was used for samples 
analysis. 
3.1.4 Particle Size Analysis (In-line Parsum Probe®) 
Parsum Probe IPP®80 (Malvern Instruments) was used to analyze particle size in real time and 
data was processed using a Log Analyzer macro. Buffer size of 500 was selected from optimization 
of probe for particle size measurement. Particle probe loading was 30% and data was logged in 
every 2 secs. Real time particle size distribution data were collected by the Parsum Runtime V8.01 
software processed by the Log Analyzer Macro. 
3.1.5 Granule Porosity 
The milled granules were characterized for the percentage porosity using Micromeritics GeoPyc 
Envelope density analyzer. The weighed sample was placed in a bed of DryFlo, and the DryFlo is 
agitated and gently consolidated about the sample. The GeoPyc collected the displacement data, 
performed the calculations and reported the percentage porosity. The true density value obtained 
from the Accu-pyc helium pycnometer (Micromeritrics) was entered into Geopyc for percentage 




3.1.6 Granule Strength 
In addition, milled granule strength was evaluated using TA2i Texture Analyzer (Texture 
Technologies) in compression mode between parallel platens. Prior to measurement, granules were 
maintained in a humidity-controlled box at room temperature and 25% RH for 48 h. The granules 
size range that formed the maximum (>80%) portion of the sample were crushed using the Texture 
Analyzer. Each granule was positioned in the center of a flat testing platform, and a flat-tipped 
cylindrical stainless steel probe of 3 mm in diameter and 28.26 mm2 (A) in area was used to apply 
the load. The probe traveled at 0.1 mm/s and penetrated a distance of approximately 0.5 mm in the 
sample. Once the predetermined distance was reached, the probe was automatically withdrawn at 
0.1 mm/s. Data (force vs. displacement) were collected at a rate of 250 points per second by 
Texture Expert Exceed software for further analysis. The measurement was repeated 10 times for 
each set of granules. During each measurement, the total force F at breakage and the diameter of 
the granule dg were determined. Assuming the granule cross-sectional area to be circular in the 
plane of the punch, the compression strength (σ) was calculated (Bika, Tardos, Panmai, Farber, & 
Michaels, 2005). 
σ = F/A 
3.1.7 Tablet Hardness 
Tablets were characterized for hardness and in-vitro dissolution. Ten tablets were randomly 
selected and tested for their hardness (Hardness tester, Schleuniger). An additional ten tablets were 
randomly selected and tested for their thickness using a digital Vernier caliper (Montana).   
 
3.1.8 Tablet In-vitro dissolution 
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In- vitro drug release was measured using USP dissolution apparatus II set at 50 rpm and 37°C. 
The test dissolution media were 700 ml of 0.1N HCl (pH 1.2) for the first 2 h, then 200 ml of 0.2 
M tribasic sodium phosphate (pH 12.5) to provide a final pH of 6.8 for 24 h (media were 
maintained at 37 °C) to simulate the tablet transit from stomach (pH 1.2) to the intestine (pH 6.8). 
The drug release studies were conducted in triplicates and the mean values were plotted versus 
time. A Waters High performance liquid chromatography (HPLC) system equipped with a Water 
600 binary pump, Waters 2489 UV/detector, and Waters 717 plus auto-sampler (Waters 
Technologies Corporation, Milford, USA) and a Phenomenex Luna 5um C18 (2) 250 x 4.6 mm 
column (Torrance, CA, USA) were used at a detection wavelength of 254 nm. The mobile phase 
consisted of Methanol and water at a ratio of 35:64:1 (v/v). The mobile phase flow rate was 
maintained at 1.0mL/min. and an injection volume of was 10 μL was used HPLC data was 
analyzed using Empower V. software (Milford, MA, USA) (Park, Lee, Kang, Tiwari, & Repka, 
2017). 
4. Results and Discussion 
 
4.1 Differential Scanning Calorimetry 
Figure 31 depicts the tg of Affinisol
®100 LV to be 120°C. Also, stearic acid and xylitol melted at 
60°C and 70°C respectively and reduced the tg of Methocel
®100LV to 140°C. Hence 
Affinisol®100 LV was granulated at temperatures below 120°C, whereas a plasticizing melt 
granulating agent such as stearic acid and xylitol were used to process Methocel®100LV at a 
temperature below 180°C (tg). The melt binders acted as plasticizing agents to reduce the tg of 




Figure 27: Differential Sanning Calorimetry thermograms of the extruded polymers with melt 
binders 
4.2 Particle Size Analysis (In-line Parsum Probe®) 
Parsum Probe IPP®80 data suggested that particle size of granules prepared using 
Affinisol®100LV was more uniform than those prepared with Methocel®100LV. From Figure 32 






     (B) 
 (C) 
Figure 28: 3D plot for influence of screw configuration and formulation variable on particle size 




This can also be represented by the number of kneading blocks and the presence of distributive 
elements (DME). The addition of the second mixing block towards the end in SC1 and SC2 
resulted in particle size breakage as opposed to the presence of the first kneading block in the start 
in all of the screw design which was critical in formation of granules. On comparison of the order 
of particle size, the presence of second kneading block was more critical to particle size reduction 
than the presence of distributive element (DME) as D50 from SC1<SC3. The granules prepared 
from SC3 were more uniform or homogenous due to breakage due to deformation of the pellet 
from all sides whereas the materials extruded with SC1, SC2 demonstrate a larger mass loss during 
crushing and chipping occurring in between the kneading elements and between the kneading 
element and the barrel wall. From Figure 33 (A) (B) (C) it can be confirmed that the screw 
configuration variable was of most significant impact (p<0.05).  
    (A) 
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    (B) 
 
     (C) 
Figure 29: Pareto chart for influence of input variables on particle size 
(A) D10 (B) D50 (C) D90  
 
4.3 Scanning Electron Microscopy 
The particle morphology observed from SEM analysis showed uniform, compact and smooth 
surface granules for Affinisol®100LV in Figure 34 (A) (B), compared to non-uniform, rough 
surface granules for Methocel®100LV in Figure 34 (C) (D).  The surface of compact 
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Affinisol®100LV granules will lower the diffusion of water into the matrix structure as opposed 
to rough and size reduced granule structure of Methocel®100LV granules which might aid in 
diffusion of water into the matrix of polymer. Figure 34 (E), (F), (G) show the structure of pure 
polymers and theophylline. Affinisol®100LV had more rounded particles, which are better to 
compress as opposed to crystalline particles of Methocel®100LV.   
 
       





     
     
 
Figure 30: SEM Images of granules processed at higher temperature and SC3 formulation  
(A)&(B) Affinisol® 100LV theophylline granules (x25, x100); (C) & (D) Methocel®100LV 
with 10% stearic acid theophylline granules (x25, x100) (E)& (F) Methocel®100LV with 10% 
xylitol theophylline granules (x25, x100) (G) Pure Affinisol® 100LV (H) Pure 






4.4 Milled granule flowability 
Granule flowability and compactability affects the die filling and tablet mechanical characteristics; 
therefore, it is essential to study the granule flow properties. Various tests have been performed on 
all formulations such as bulk density, tapped density, Carr’s index and Hausner’s ratio. According 
to the flow property classification of USP, granules should have a Carr’s index between 10.0 and 
18.0%, whereas Hausner’s ratio should be less than 1.25. When the Carr’s index and Hausner’s 
ratio are adequate, the powder flows at minimum bulk density and consolidates to maximum 
density inside the die, prior to compression. Carr’s index was observed to be higher for 
unprocessed physical blends of HPMC and theophylline (45%) compared to the HME processed 
granules (12.7%), which indicated better flowability of the granules. Specifically, from figure 38 
Carr’s index was seen to be impacted due to the formulation type and the temperature of operation. 
Methocel®100LV granules had higher Carr’s index at lower temperature and lower Carr’s index 
at higher temperature Figure 37 (A) (B) (C). Carr’s index of Affinisol®100LV granules did not 
vary significantly with the change of extrusion temperature. In general, formulations made with 
SC3 did not vary with the formulation type or temperature, except Methocel®100LV stearic acid 
granules which had higher Carr’s index at lower temperature due lesser strength and size of 
granules due to cutting action of the DME. The Hausner’s ratio also followed the same trend as 






       (A) 
      (B) 
      (C) 
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Figure 31: Impact of process and formulation variables on Hausner’s ratio (A) Screw 
confguration 1 (B) Screw configuration 2 (C) Screw configuration 3 (Methocel® 100LV with 
10% stearic acid , Methocel® 100LV with 10% xylitol , Affinisol® 100LV ) 
 
 
Figure 32: Pareto chart for influence of input variables on Hausner’s ratio 
 
        (A) 
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      (B) 
        (C) 
Figure 33: Impact of temperature on Carr’s index  of different formulations  
(A) Screw confguration 1 (B) Screw configuration 2 (C) Screw configuration 3 





Figure 34: Pareto chart for influence of input variables on Carr’s index 
4.5 Compression strength 
The granule strength was impacted significantly (p<0.05) by formulation type (Figure 40). The 
granules prepared with Methocel®100LV and xylitol had significantly greater strength compared 
to Methocel®100LV and stearic acid (Figure 39). This was due to lesser viscosity of xylitol 
compared to stearic acid and hence better spreadability over greater surface area and form greater 
bridges between powder particles. The properties of granules prepared from higher temperature of 
operation (tg of polymer) within the same formulation had higher strength compared to lower 
temperature (melt temperature of melt binder) as greater amount of granulation was observed in 
the former case, which increased the strength of solid bridges formed. Affinisol®100LV polymer 
was rubbery at both the temperatures where all the polymer particles were activated as opposed to 
Methocel®100LV at lower temperature only the melt binder attracts additional polymer and API 





Figure 35: One factor- Plot of influence of formuation variables on strength (N/mm2) of granules  
 
 





4.6 Percentage porosity 
The formulation, temperature and screw configuration, all had significant impact on the percentage 
porosity as seen in the Pareto chart in Figure 42. Affinisol®100LV formulation, did not have 
significant difference in percent porosity at different temperature or different screw configuration 
(Figure 41A). Methocel®100 LV with stearic acid had lower percent porosity as compared to 
Affinisol®100 LV as the granules with Methocel®100 LV were easily size reduced due to low 
strength in the processing whereas Affinisol®100 LV had higher granule size due to greater 
strength and retained their basic structure. The pores inside the Affinisol®100 LV granules were 
hence retained while the Methocel®100 LV granules due to size reduction and particle breakage 
had reduced pores (Figure 41 B). All of the Methocel®100 LV with xylitol formulation had similar 
porosity as Methocel®100 LV with stearic acid except the one with SC3 due to least reduction of 
particle size and hence the pores in that formulation (Figure 41 C).  
   (A) 
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     (B) 
 
       (C) 
Figure 37: % Porosity of the granules (A) Affinisol®100LV (B) Methocel®100LV with 10% 





Figure 38: Pareto chart for influence of input variables on percent porosity 
 
4.7 Tablet hardness 
The hardness of tablets prepared from Methocel®100LV granules was dependent on the extrusion 
temperature and formulation type (Figure 44). The tablets prepared from Methocel®100LV 
granules using stearic acid had higher hardness at lower temperature and lower hardness at higher 
temperature (Figure 43A). The hardness of tablets prepared from Affinisol®100LV granules were 







Figure 39: Effect of process variables on Hardness of tablet (SC1 , SC2 , SC3 )  
(A) Methocel®100LV with 10% stearic acid (B) Methocel®100LV with 10% xylitol 




Figure 40: Pareto chart for evaluation of main effects and interaction between input variables on 
hardness of tablet  
 
4.8 In-vitro Tablet dissolution 
Percent drug dissolved was one of the output parameters investigated, where percent of drug 
dissolved at the end of 12 hours was plotted.  Dissolution profiles revealed sustained release 
behavior for 12-16 h, which was dependent on formulation significantly (Figure 47). 
Affinisol®100LV granules exhibited the highest sustained release profile followed by 
Methocel®100LV granules using stearic acid and Methocel®100LV granules with xylitol (Figure 
45). It was observed all granule formulations (except Methocel®100LV + xylitol) extruded at lower 
temperatures using SC3, exhibited lower in-vitro release in 12h (73%) (Figure 46). Xylitol acted 
as a pore former which increased the diffusion of drug into the dissolution matrix. The dissolution 




Figure 41: One factor- Impact of formulation variables on the in-vitro dissolution rate  
 
     
Figure 42: Interaction plot- Impact of formulation variables and screw configuration on the in-
vitro dissolution rate (SC1 , SC2 , SC3 ) (A) Low temperature (B) High temperature 
 
Figure 43: Pareto chart for evaluation of main effects and interaction between input variables on 




4.9 Desirability index 
The desired or optimum process and formulation parameters were plotted (Figure 48) from Design 
Expert® software which resulted in lowest value of in-vitro dissolution (Y1), low Carr’s index and 
Hausner’s ratio (Y2), high granule strength (Y3), unimodal granule size distribution (Y4), high 
hardness (Y5). The optimum process conditions (desirability of 0.75) were Screw configuration 3, 
Affinisol®100LV as release modifying polymer, higher (120°C) temperature of extrusion to 
achieve <80% in-vitro dissolution in 12 hours, Carr’s index of 9, Hausner’s ratio of 1.1, granule 
size distribution of 800-2000 µm, granule strength of 10478 N/mm2 and tablet hardness of 8.  
 









Particle size of granules depended on screw configuration (p<0.05) and reduced with addition of 
2nd mixing block and DME. SC3 resulted in producing uniform and larger granules. Parsum probe 
IPP®80 in-line particle size analyzer was successfully applied as a PAT tool to study the impact of 
processing and formulation parameters on twin screw melt granulation processes. The 
understanding of the geometric aspects of the screw elements and their effect on the maximum 
size of granules from a real time particle size analysis probe in a twin Screw Granulator is a step 
towards tailored granule size distributions. By choosing a certain type and design of the screw 
elements, the breakage mechanisms in the granulator can be modified resulting in broad mono-
modal or bimodal granule size distributions. Affinisol®100LV holds greater promise to serve as a 
sustained release polymer matrix with 70% drug loading to achieve release over 18hrs. Also, the 
granule properties of the Affinisol®100LV granules did not vary significantly with changing 











IV. CHAPTER  
Monitoring the molecular interaction of Indomethacin with co-former during hot-melt 





With the advent of combinatorial chemistry and high throughput screening, most of the newly 
synthesized small molecules in the drug discovery pipelines have been extremely insoluble in 
aqueous media. As a consequence, they have low dissolution rates and exhibit poor and variable 
bioavailability after oral administration to animals and humans. Many enabling methodologies, 
including salt formation, co-crystallization, particle size reduction, lipid-based delivery, and 
amorphous solid dispersion, have been employed to enhance dissolution rate and oral 
bioavailability of such compounds (Aakeröy, Fasulo, & Desper, 2007; Pudlas et al., 2015). 
However, each of these methodologies has its own limitations. In recent years, there has also been 
much interest in amorphous solid dispersions. At the early stage of drug development, amorphous 
solid dispersions are usually prepared by spray drying, which requires large volumes of organic 
solvents to simultaneously dissolve drug and carrier, thus creating solvent handling issues during 
manufacturing. The physical instability due to recrystallization of the drug from, solubilized or 
amorphous state, is also a major issue for the amorphous solid dispersion (Qian, Huang, & Hussain, 
2010). Salt formation of these poorly water soluble moieties is an excellent method to overcome 
such disadvantages. However, the manufacture of salts on relatively large scales remains a 
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complex process. Commonly used manufacturing techniques for salt formation require very large 
volumes of organic solvents and high temperatures to dissolve drugs and salt forming agents, 
enable chemical reaction, and obtain salts in crystalline states. Moreover, these are batch processes 
rather than continuous ones. Since salts may be considered as new APIs and thus enjoy patent 
protection, they are considered more valuable than co-crystals in pharmaceutical development. 
Salts are generally prepared by acid–base reaction in relatively large volumes of organic solvents, 
followed by crystallization (Lee et al., 2017). In this study, the potential for preparing a 
pharmaceutical salt between Indomethacin (Indo) (water solubility 0.9 µg/ml, pKa 4.5) and 
Tromethamine (Tro) (highly water soluble, pKa 8.1) by a novel solvent-free method using a twin-
screw melt extruder was investigated. In-addition, the continuous preparation of the salt was 
monitored via an in-line FT-NIR probe to determine the extrusion conditions that result in 
complete interaction between the weakly acidic API and basic co-former to obtain a crystalline 
salt. The pH–solubility relationship between Indo and Tro in aqueous medium was first 
determined, which demonstrated that 1:1 salt formation between them was feasible (pHmax 8.1; salt 
solubility 19.3 mg/mL).  Salts were also prepared by solution crystallization from 200 proof 
ethanol and compared with those obtained by melt extrusion.  
2. Materials 
 
Indomethacin (C19H16ClNO4, ≥ 98% purity, MW: 357.79 g/mol, M.P. 162°C, pKa 4.5) was 
purchased from Combi-Blocks, Inc. (San Diego, California). Tromethamine (C4H11NO3, ≥99% 
purity, MW: 121.136g/mol, M.P. 142°C (metastable polymorph) 171°C (stable polymorph), pKa 
8.07) was obtained from AK Scientific, Inc. (Union City, California). All organic solvents and 






3.1 FTIR spectroscopy 
Spectra were obtained using an attenuated total reflectance (ATR) accessory (single reflection 
germanium crystal) and a DLaTGS detector. The resolution was 4 cm−1, and 32 scans were 
acquired in the range of 4000–400 cm−1. The peak positions were determined using Resolutions 
Pro software peak picking function. 
3.2 X-ray Diffraction 
Morphology of the powder samples was investigated using a Benchtop X-ray diffraction 
instrument; Model Miniflex 600 (Rigaku, Woodlands, TX) with primary monochromated radiation 
(CuK radiation source, λ = 1.54056 A°). The instrument was operated at an accelerating voltage 
of 40 kV and 15 mA. All samples were subjected to the same program; scanned over a 2h range 
of 5–40° 2θ at a step size of 0.04° 2θ/s, a dwell time of 2 s and scan speed of 1°/min. 
3.3 Differential Scanning Calorimetry (DSC) 
DSC studies were performed with a TA Instruments (Q25) differential scanning calorimeter (DSC) 
equipped with Trios software. Samples were prepared by sealing 5-7 mg of pure API, physical 
mixtures, blank formulations, drug loaded extrudates in non- hermetically sealed aluminum pans 
and heated from the temperature range of 30°C to 100°C at the heating rate of 20°C/min under an 
inert nitrogen atmosphere at a flow rate of 20 mL/min. 
3.4 In-vitro dissolution 
In-vitro dissolution was carried out using USP (Type I – Basket apparatus) using pH 7.2 phosphate 
buffer medium under sink conditions maintained at 37°C according to the USP guidelines. The 
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milled extrudates were filled into capsules where a dose equivalent to 50mg of Indo was accurately 
weighed into one capsule. The in-vitro dissolution samples were taken at 5, 15, 30, 45, 60, 120 
mins and analyzed using reverse phase HPLC method. Analysis was performed using C-18 column 
(150mm×4.6 mm, 5 µm), mobile phase of 50:50 acetonitrile and water containing 0.2% phosphoric 
acid at 0.8 ml/min flow rate at 254 nm detection wavelength (Nováková, Matysová, Havlíková, & 
Solich, 2005).      
3.5 Proton and Carbon Nuclear Magnetic Resonance (1H and 13C NMR) 
Solution Proton and Carbon Nuclear Magnetic Resonance (1H and 13C NMR) was performed in 
an NMR spectrometer (Bruker AM-400 Spectrometer) and used to determine the identity of a 
substance and formation of salt by determining the number of hydrogen atoms. Samples in the 
present study were dissolved in deuterated DMSO for measurement. NMR spectra were acquired 
using a BBI 1H/D-BB Z-GRD probe with a scan number of 16 at 298 K, and the acquisition time 
was 1 min and 32 s. In addition, Dept 135 analysis was performed to confirm the salt formation.  
3.6 Indomethacin and tromethamine salt preparation 
3.6.1 Hot-melt extrusion 
The physical blend of Indo and Tro in a 1:1 molar ratio was prepared in a V-Blender for uniform 
mixing, and the blend was then fed into a twin screw extruder with screw Configurations depicted 
in Figure 49. The operating parameters and conditions were listed in Table 9. During extrusion, 
the physical blend converted to the tacky semisolid melt and then formed a thin layer on the inner 
contact surface of the extruder barrel. Consequently, much viscous dissipation was created among 
the tacky melt, the co-rotating twin screws, and the inner surface of the extruder barrel. Due to the 
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conversion of the blend to tacky material during extrusion, it took from 3-7 mins between the 
feeding of the blend into the extruder and the exit of the product (residence time).  












F-1 135 200 15 3.2 1 
F-2 135 200 7 1.6 1 
F-3 145 200 7 1.6 1 
       F-4  135 100 7 1.6 1 
F-5 135 100 15 3.2 1 
F-6 145 100 7 1.6 1 
F-7 145 100 15 3.2 1 
F-8 155 100 7 1.6 1 
F-9 155 100 15 3.2 1 
F-10 135 100 15 3.2 2 
Table 9: Extrusion conditions used for preparation of Indo: Tro salts on 11mm Thermo Scientific®  
 
 
Figure 45 (A): Screw configuration 1 and 2 used for formulation of Indo-Tro salt  
Screw configuration 1 
Screw configuration 2 
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                       (i) Indomethacin                             (ii) Tromethamine 
Figure 49 (B): Molecular structure of indomethacin and Tromethamine 
3.6.2 Solvent evaporation 
1:1 molar ratio of Indo and Tro were accurately weighed and blended using a V-Blender for 15 
mins. The physical mixture was added to 200 proof ethanol (not saturated) and stirred using a 
magnetic stir bar until complete clear solution was achieved. This solution was rotary evaporated 
at 60°C at 200 rpm for 2 hours and dried using a vacuum desiccator until constant weight was 
achieved. 1:1 salt of Indo:Tro was thus achieved using solvent evaporation technique.   
3.7 FT-NIR study  
Diffuse reflectance NIR spectra were continuously collected inline and non-invasively during hot-
melt extrusion using a Fourier- Transform NIR spectrometer (Thermo Fisher Scientific, Antaris II 
near-IR analyzer) equipped with an InGaAs detector, a quartz halogen lamp, and a fibre-optic 
probe which was mounted in the extrusion die. Spectra were collected every 16 s in the 9000–4500 





4. Results and Discussion 
 
A general idea of the possible mechanism of salt formation by TSE may be obtained from previous 
investigations in preparing known co-crystals via TSE, which revealed that co-crystals may be 
mediated through eutectic formation. In general, the eutectic melt undergoes super-saturation that 
results in crystallization from the melt to form a co-crystal, whose melting is higher than the 
eutectic temperature. The phenomenon of eutectic formation can be observed by hot-stage 
microscopy. 
 
4.1 FTIR spectroscopy 
From Figure 50 (A), the overlay plot of FTIR spectra of pure indomethacin, pure tromethamine, 
Indo:Tro 1:1 and Indo:Tro 2:1 blends, obtained by solvent evaporation. Salt formation was 
confirmed by the disappearance of the C=O carboxyl functional group at around 1710 cm-1 and 
appearance of COO- at 1550 cm-1 in Indo: Tro 1:1, which was not seen in Indo: Tro 2:1 (Coates, 
2000). In addition, from figure 50 (B) (C) (D) (E) which corresponds to F-1, F-2, F-3, F-10 hot 
melt extrudates, shift of the asymmetric ionized COO- was seen in formulations F-1, F-2, F-10 but 
not in F-3. F-3 showed a broad shoulder at 1710 cm-1 indicating presence of crystalline Indo 
precipitated from amorphous salt. Thus optimum salt formation was seen when extrusion was 




Figure 46 (A): Overlay spectra of pure indomethacin, tromethamine, Indo:Tro 1:1 and 2:1 SE 
(solvent evaporation) formulation 
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Figure 50 (C): FTIR spectra of Indo:Tro hot melt extrudate F-2 
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Figure 50 (E): FTIR spectra of Indo:Tro hot melt extrudate F-10 
 
 
4.2 Differential Scanning Calorimetry 
The DSC thermograms in Figure 51 (A) shows that Pure Indo melted at 160°C and pure TRO 
melted at 148 °C (metastable polymorph) and 174 °C, respectively. The Indo: Tro hot-melt 
extrudates, specifically F-1, F-2, F-10 showed endothermic melting events below the individual 
melting points. These low “eutectic-like” endothermic events were due to the suppression of Indo 
melting in the presence of Tro. The salt obtained by hot-melt extrusion had a melting point of 142 
°C which was similar to the melting point of the salt prepared by solvent evaporation (SE). F-3 
was observed to be amorphous due to extrusion above the melting temperature of the salt. It also 
showed small melting endotherm at 160°C (not seen in image due to overlay) which corresponds 
to Indo which might have precipitated out. Also, F-1 and F-2 had comparable enthalpy of melting 
compared to F-10 which had greater enthalpy of melting. Figure 51 (B) shows that F-4 was also 
crystalline sals of Indo:Tro having a melting point similar to the salt obtained from solvent 
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crystallization. Thus it could be concluded that extrusion conditions of  high feed rate (3.2g/min), 
low screw speed (100 rpm), low temperature (135 °C), low shear screw configuration were 
essential for formation of crystalline salt of Indo.   
 
Figure 47 (A): DSC thermograms of Pure Indo, Pure Tro and 1:1 hot melt extrudates 
 
 






4.3 X-ray Diffraction 
Figure 52 (A) (B) depicts the X-ray diffractograms of crystalline ( F-1, F-2, F-10, SE) and 
amorphous (F-3, F-4, F-5, F-6) formulations. It can be seen that the characteristic new 2θ peak at 
13.6° for the F-1, F-2, F-10 salt which was not present in the pure components indicates 
formulation of a third crystal structure different from Indo and Tro. F-3, F-4, F-5 was observed to 
be amorphous due to no Braggs peaks present in the diffractogram. The minimal crystallinity of 
F-4 formulation observed in previous DSC data was not detected in XRD study. The maximum 
intensity peak was observed with F-10 which implies maximum new crystal content in the 
formulation. X-Ray diffraction study confirms with the observation of DSC study (Thakral & 
Suryanarayanan, 2015). 
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Figure 52 (B) XRD diffractograms of F-3, F-4, F-5, F-6 amorphous formulation with pure 
components 
4.4 In-vitro dissolution 
From figure 53 (A) and (B), formulations F1-F3 have >85% in-vitro drug release of in first 15 
mins whereas pure Indo and physical mixture only had 5% and 52% release respectively. F-3 had 
lower drug release compared to F-1 due to small amount of crystalline indomethacin precipitated 
from amorphous salt. Formulations F-4 to F-10 also have >85% in-vitro drug release of in first 
15 mins. F-10 had the highest drug release compared to other extruded formulations due to 
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Figure 49 (A): In-vitro dissolution profile of F-1- F-3 extruded formulations 
 
 























4.5 NMR spectroscopy   
Figure 54 (A, B,C,D) depicts the 1H- NMR spectra of Pure Indo, Pure Tro, SE salt formulation, F-
2, F-10 and F-3 salt. It can be inferred from the plot that peak for –CH2 group beside the –COOH 
carboxylate (refer Figure 49 B) group in the F-1, F-3, SE salt shifts from 3.66 ppm to 3.45 ppm 
due to formation of –COO - ion. This indicates formation of salt in the extrudate as well as solvent 
evaporated formulation. The peaks for –OCH3 and –CH3 groups in Indo which occur at 3.7 ppm 
and 2.19ppm respectively stay constant in the formulations as well. The responses appearing 
between 6.5- 7.7 ppm, correspond to aromatic benzene –CH– groups of Indo which also stay 
constant in all the formulations. 13C NMR was performed to check for the formation of salt which 
would be clearly depicted than 1H- NMR study due to presence of single –CH2 group that needs 
to be monitored. From Figure 55 (A, B) it can be observed that the –CH2 and –C=O peak for the 
indomethacin which appeared at 29.5 ppm and 172.1ppm shifted to 32.8ppm and 174.4ppm 
respectively which indicated ionization of the carboxylic acid group and hence salt formation. Also 
135 DEPT analysis was used to confirm the shift of –CH2 group, as indomethacin converts to salt 
form (F-10). In 135 DEPT analysis all the –CH2 peaks appear on the bottom of the baseline while 
the –CH peaks appear on the top of the baseline. As indomethacin has only one –CH2 it was clearly 
depicted by the bottom position of the peak at 29.5ppm. The shift of bottom peak at 29.5ppm to 
top peak at 32.8ppm (due to shift of proton from –CH2 to form –CH) was observed as hence salt 



































Figure 55 (B): 13C- NMR spectroscopy(1) Pure Indo, (2) Pure Tro and (3) F-10 salt in DMSO-d6 
 






4.6 FT-NIR study  
Diffuse reflectance NIR spectra were continuously collected inline and non-invasively during hot-
melt extrusion using a Fourier- Transform NIR spectrometer (Thermo Fisher Scientific, Antaris II 
near-IR analyzer) equipped with an InGaAs detector, a quartz halogen lamp, and a fibre-optic 
probe which was mounted in the extrusion die (Fig. 2). Spectra were collected every 16 s in the 
9000–4500 cm-1 region with a resolution of 16 cm-1 and averaged over 8 scans. Data analysis was 
performed using the Result software (Version 3.0, Thermo Fisher Scientific) and TQ Analyst. 
Spectra collected in the diffuse reflectance mode mostly require spectral pre-treatment before 
analysis. The degree of scattering depends on the wavelength of the light and the refractive index 
of the sample, which causes a non-equal scatter over the whole spectrum. This can result in a 
baseline shift. Therefore, multiplicative signal correction (MSC) was used before chemometric 
analysis of the spectra. Using MSC, undesired scatter is removed from the raw spectra to prevent 
it from dominating over the chemical information within the spectra. The result of MSC pre-
processing is that each corrected spectrum has the same offset and amplitude, eliminating the 
difference in light scatter in the spectra from the different samples, before developing the 
calibration model. Furthermore, second derivative pre-processing was done after MSC correction. 
Second derivatives of NIR spectra magnify differences in spectral features provide baseline 
normalization and remove data offsets due to scattering effects and pathlength variation (Saerens 
et al., 2012). 
Figure 56 describes the FT-NIR spectra of pure indomethacin and pure tromethamine powders at 
room temperature. The peak at 6500 cm-1 is characteristic of the amine group of Tro and the peak 





Figure 52: FT-NIR spectra of Indomethacin and tromethamine powders at room temperature 
 
Figure 57 depicts the FT-NIR spectra of melting process of pure tromethamine. It can be noted 
that there is gradual increase in the intensity and sharp peak of amine group at 6500 cm-1. Also 
there is gradual appearance of the –OH peak at 7000 cm-1 at the melting process proceeds, which 
might be due to breaking of intra-molecular H-bonding in the Tro salt and hence availability of –




Figure 53: FT-NIR spectra of melting process of pure tromethamine 
Figure 58 demonstrates the FT-NIR spectra of melting process of pure indomethacin. Here the 
peak corresponding to carboxylate group at 5900 cm-1 diminishes in size due to temporary 
amorphization in the melted state.  
    




Figure 59 shows the overlay of the spectra of the melted forms of Indo and Tro respectively. Here 
it can be seen that the peaks of interest of Indo (5900cm-1) and Tro (6500 cm-1) can be selected for 
analyzing the salt formation as they do not overlap in the other spectra and hence characteristic to 
model interaction.   
 
Figure 55: Comparison of Indomethacin and tromethamine hot-melts 
 
Figure 60 shows the real time in-line data collected from the Antaris II probe. At 135oC, the hot 
melt has opaque salt form of particles. The scattering from solid particles generated strong 
reflectance signal (low spectral baseline) and short penetration distance (low peak height). The hot 
melt became clear liquid at 145oC and above, and the large baseline drift was the result of weak 



























Figure 56: Absorption FT-NIR spectra collected during experiment of 1:1 
Indomethacin:Tromethamine 
In Figure 61, the spectral peak area at 5900 cm-1 was used for the penetration distance or 
pathlength correction. Since this peak is mainly the response from Indomethacin, the normalized 
spectra will more relate to per unit weight of Indomethacin. 
 
Figure 57: Spectral pathlength normalization 
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Figure 62 After application of Norris derivative to the spectral region of interest, the spectral 
variation in the intensity of the amine peak and the carboxylate group could be monitored. A 
statistical model is required to measure the difference in intensity of this signal.  
 
Figure 58: Second Norris derivative of complete FT-NIR spectra 
Figure 63 depicts the calibration of the Partial Least Square (PLS) model used to determine the 
correlation between the % crystalline salt formation and peak intensity from 6100 cm-1 to 5800 
cm-1. The lesser intensity of carboxylate peak at lower temperature (135°C) implied greater 
crystalline salt formation reaction compared to higher temperature extrudates (145°C and above) 
where the interaction resulted in amorphous salt formation. From the calibration we could achieve 
a co-relation of greater than 95%. The crystalline salts achieved from F-1, F-2, F-4 and F-10 were 
analyzed and the % crystallinity mentioned in Table 10. F-10 was the formulation with greatest 
crystalline salt formation.  
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Figure 59: Calibration of the peak intensity from 6100 cm-1- 5800 cm-1 












F-1 135 200 75.8 3.2 1 
F-2 135 200 80.5 1.6 1 
F-3 145 200 - 1.6 1 
       F-4  135 100 50.1 1.6 1 
F-5 135 100 - 3.2 1 
F-6 145 100 - 1.6 1 
F-7 145 100 - 3.2 1 
F-8 155 100 - 1.6 1 
F-9 155 100 - 3.2 1 
F-10 135 100 98.5 3.2 2 
 








Salt formation of a poorly water soluble compound was successfully achieved using hot-melt 
extrusion. The product characteristics were evaluated using in-line FT-NIR and other solid state 
characterization tools to better understand the influence of processing parameters. The extrusion 
condition of feed rate 3.2g/min, 100 rpm, 135 °C screw configuration 2 resulted in highest 
crystalline salt formation of 98.5% crystallinity. The extrusion at 145 °C and above resulted in 
amorphization of the API and resulting salt formulation. It could be concluded that temperature 
and shear stress were the two significant parameters to affect the product quality. At higher 
temperature and shear stress (by increasing kneading blocks in screw configuration and screw 
speed) resulted in breakdown of the possible crystalline nature of the salt. In-line FT-NIR was 
successfully applied as a PAT tool to detect the optimal processing conditions for salt formation 







































Aakeröy, C. B., Fasulo, M. E., & Desper, J. (2007). Cocrystal or salt: does it really matter?        
Molecular Pharmaceutics, 4(3), 317-322. 
Bahloul, B., Lassoued, M. A., & Sfar, S. (2014). A novel approach for the development and 
optimization of self emulsifying drug delivery system using HLB and response surface 
methodology: application to fenofibrate encapsulation. International journal of 
pharmaceutics, 466(1), 341-348.  
Balakrishnan, P., Lee, B.-J., Oh, D. H., Kim, J. O., Hong, M. J., Jee, J.-P., . . . Yong, C. S. (2009). 
Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug 
delivery system (SEDDS). European Journal of Pharmaceutics and Biopharmaceutics, 
72(3), 539-545.  
Bari, H. C., Doijad, R. C., More, H. N., & Disouza, J. I. (2011). Design and optimization of 
chlordiazepoxide solid self-microemulsifying drug delivery system. J Pharm Res, 4(2), 
369-372.  
Berge, S. M., Bighley, L. D., & Monkhouse, D. C. (1977). Pharmaceutical salts. Journal of 
pharmaceutical sciences, 66(1), 1-19.  
Bika, D., Tardos, G., Panmai, S., Farber, L., & Michaels, J. (2005). Strength and morphology of 
solid bridges in dry granules of pharmaceutical powders. Powder Technology, 150(2), 104-
116.  
Coates, J. (2000). Interpretation of infrared spectra, a practical approach. Encyclopedia of 
analytical chemistry.  
Cole, E. T., Cadé, D., & Benameur, H. (2008). Challenges and opportunities in the encapsulation 
of liquid and semi-solid formulations into capsules for oral administration. Advanced drug 
delivery reviews, 60(6), 747-756.  
Dixit, R. P., & Nagarsenker, M. (2010). Optimized microemulsions and solid microemulsion 
systems of simvastatin: characterization and in vivo evaluation. Journal of pharmaceutical 
sciences, 99(12), 4892-4902.  
Gumaste, S. G., Pawlak, S. A., Dalrymple, D. M., Nider, C. J., Trombetta, L. D., & Serajuddin, A. 
T. (2013). Development of solid SEDDS, IV: effect of adsorbed lipid and surfactant on 
99 
 
tableting properties and surface structures of different silicates. Pharmaceutical research, 
30(12), 3170-3185.  
Gupta, V., Hwang, B. H., Doshi, N., & Mitragotri, S. (2013). A permeation enhancer for increasing 
transport of therapeutic macromolecules across the intestine. Journal of controlled release, 
172(2), 541-549.  
Kim, D. W., Kang, J. H., Oh, D. H., Yong, C. S., & Choi, H.-G. (2012). Development of novel 
flurbiprofen-loaded solid self-microemulsifying drug delivery system using gelatin as solid 
carrier. Journal of microencapsulation, 29(4), 323-330.  
Kocbek, P., Baumgartner, S., & Kristl, J. (2006). Preparation and evaluation of nanosuspensions 
for enhancing the dissolution of poorly soluble drugs. International journal of 
pharmaceutics, 312(1), 179-186.  
Lee, H. L., Vasoya, J. M., Cirqueira, M. d. L., Yeh, K. L., Lee, T., & Serajuddin, A. T. (2017). 
Continuous Preparation of 1: 1 Haloperidol–Maleic Acid Salt by a Novel Solvent-Free 
Method Using a Twin Screw Melt Extruder. Molecular Pharmaceutics, 14(4), 1278-1291.  
Mu, B., & Thompson, M. (2012). Examining the mechanics of granulation with a hot melt binder 
in a twin-screw extruder. Chemical engineering science, 81, 46-56.  
Nie, H., Xu, W., Ren, J., Taylor, L. S., Marsac, P. J., John, C. T., & Byrn, S. R. (2016). Impact of 
metallic stearates on disproportionation of hydrochloride salts of weak bases in solid-state 
formulations. Molecular Pharmaceutics, 13(10), 3541-3552.  
Nováková, L., Matysová, L., Havlíková, L., & Solich, P. (2005). Development and validation of 
HPLC method for determination of indomethacin and its two degradation products in 
topical gel. Journal of pharmaceutical and biomedical analysis, 37(5), 899-905.  
Park, J.-B., Lee, B.-J., Kang, C.-Y., Tiwari, R. V., & Repka, M. A. (2017). Process analytical 
quality control of tailored drug release formulation prepared via hot-melt extrusion 
technology. Journal of Drug Delivery Science and Technology, 38, 51-58.  
Patel, D. P., Li, P., & Serajuddin, A. T. (2016). Enhanced microemulsion formation in lipid-based 
drug delivery systems by combining mono-esters of mediumchain fatty acids with di-or 
tri-esters. Journal of Excipients and Food Chemicals, 3(2).  
100 
 
Patil, H., Tiwari, R. V., Upadhye, S. B., Vladyka, R. S., & Repka, M. A. (2015). Formulation and 
development of pH-independent/dependent sustained release matrix tablets of ondansetron 
HCl by a continuous twin-screw melt granulation process. International journal of 
pharmaceutics, 496(1), 33-41.  
Pudipeddi, M., Serajuddin, A., Grant, D., & Stahl, P. (2002). Solubility and dissolution of weak 
acids, bases, and salts. Handbook of Pharmaceutical Salts, Properties, Selection, and Use. 
Zurich, Switzerland: Verlag Helvetica Chimica Acta and Weinheim, Wiley-VCH, 
Weinheim, Federal Republic of Germany: Wiley-VCH, 19-39.  
Pudlas, M., Kyeremateng, S. O., Williams, L. A., Kimber, J. A., van Lishaut, H., Kazarian, S. G., 
& Woehrle, G. H. (2015). Analyzing the impact of different excipients on drug release 
behavior in hot-melt extrusion formulations using FTIR spectroscopic imaging. European 
Journal of Pharmaceutical Sciences, 67, 21-31.  
Qian, F., Huang, J., & Hussain, M. A. (2010). Drug–polymer solubility and miscibility: stability 
consideration and practical challenges in amorphous solid dispersion development. Journal 
of pharmaceutical sciences, 99(7), 2941-2947.  
Qiao, N., Wang, K., Schlindwein, W., Davies, A., & Li, M. (2013). In situ monitoring of 
carbamazepine–nicotinamide cocrystal intrinsic dissolution behaviour. European Journal 
of Pharmaceutics and Biopharmaceutics, 83(3), 415-426.  
Rajput, L. (2014). Stable crystalline salts of haloperidol: A highly water-soluble mesylate salt. 
Crystal Growth & Design, 14(10), 5196-5205.  
Saerens, L., Dierickx, L., Quinten, T., Adriaensens, P., Carleer, R., Vervaet, C., . . . De Beer, T. 
(2012). In-line NIR spectroscopy for the understanding of polymer–drug interaction during 
pharmaceutical hot-melt extrusion. European Journal of Pharmaceutics and 
Biopharmaceutics, 81(1), 230-237.  
Saxena, V., & Hussain, M. D. (2012). Poloxamer 407/TPGS mixed micelles for delivery of 
gambogic acid to breast and multidrug-resistant cancer. International journal of 
nanomedicine, 7, 713.  
101 
 
Schilling, S. U., & McGinity, J. W. (2010). Novel application of hot-melt extrusion for the 
preparation of monolithic matrices containing enteric-coated particles. International 
journal of pharmaceutics, 400(1), 24-31.  
Schmolka, I. R. (1977). A review of block polymer surfactants. Journal of the American Oil 
Chemists' Society, 54(3), 110-116.  
Serajuddin, A. T. (1999). Solid dispersion of poorly watersoluble drugs: Early promises, 
subsequent problems, and recent breakthroughs. Journal of pharmaceutical sciences, 
88(10), 1058-1066.  
Sha, X., Yan, G., Wu, Y., Li, J., & Fang, X. (2005). Effect of self-microemulsifying drug delivery 
systems containing Labrasol on tight junctions in Caco-2 cells. European Journal of 
Pharmaceutical Sciences, 24(5), 477-486.  
Shah, A. V., & Serajuddin, A. T. (2012). Development of solid self-emulsifying drug delivery 
system (SEDDS) I: use of poloxamer 188 as both solidifying and emulsifying agent for 
lipids. Pharmaceutical research, 29(10), 2817-2832.  
Stephenson, G. A., Aburub, A., & Woods, T. A. (2011). Physical stability of salts of weak bases 
in the solidstate. Journal of pharmaceutical sciences, 100(5), 1607-1617.  
Thakral, S., & Suryanarayanan, R. (2015). Salt formation during freeze-drying-an approach to 
enhance indomethacin dissolution. Pharmaceutical research, 32(11), 3722-3731.  
Vasanthavada, M., Wang, Y., Haefele, T., Lakshman, J. P., Mone, M., Tong, W., . . . Abu, T. 
(2011). Application of melt granulation technology using twinscrew extruder in 
development of highdose modifiedrelease tablet formulation. Journal of 
pharmaceutical sciences, 100(5), 1923-1934.  
Wahl, P. R., Treffer, D., Mohr, S., Roblegg, E., Koscher, G., & Khinast, J. G. (2013). Inline 
monitoring and a PAT strategy for pharmaceutical hot melt extrusion. International journal 







   
EDUCATION  
Doctor of Philosophy (Ph.D.) Pharmaceutics                                                                     Aug 2018 
University of Mississippi (UM), GPA: 3.92/4.0    
Dissertation: Application of Design of Experiments (DOE) and Process Analytical Technology 
(PAT) towards Pharmaceutical extrusion processes. (Advisor: Dr. Michael Repka)                                                  
M.S. Industrial Pharmacy                                                                                                     Aug 2013                    
St. John’s University, NY, GPA: 3.8/4.0                                                                          
Thesis: Ionic Liquid: A Novel Approach for Improving the Dissolution Rate of a Poorly Water Soluble 
Drug.  
Bachelor of Science (B.S.) in Pharmacy                                                                              May 2010 
University of Mumbai, India, GPA: 3.7/4.0                                                                                                               
 
PROFESSIONAL EXPERIENCE 
Patheon Pharmaceuticals, OH, USA                                                                        Apr 2018-current 
Sr. Scientist I (Pharmaceutics & Process Technology) 
 
AbbVie Inc., Lake county, IL, USA                                                                   May 2016- Aug 2016 
Graduate Summer Intern (Manufacturing Science & Technology, Oral drug products) 
 
Hands-on course in tablet technology at University of Mississippi               Sept 2014 – Dec 2017 
Lab instructor 
 
AWARDS AND HONORS 
Travelship for 11th World meeting Pharmaceutics, Biopharm., Pham. Technology, Spain    Mar 2018                          
Texture Technologies® sponsored scholarship, AAPS 2017-AM                                            Oct 2017 
Dissertation fellowship, Dept. of Pharmaceutics, University of Mississippi                           Nov 2017                                                        
Manufacturing Science & Engineering section Travelship Award for best poster, AAPS     Aug 2016  
Amgen sponsored Graduate Student Travelship Award for best poster, AAPS                       Oct 2015 
Best Graduate Poster Award, 4th place Society of Plastic Engineering (SPE) conference      Mar 2015 
Honor Member, Rho-Chi Society, University of Mississippi                                                   Jan 2015 
Astra Zeneca sponsored Graduate Student Travelship Award for best poster, AAPS            Nov 2014                   





University of Mississippi (UM)-AAPS student chapter                                   Sept 2014- Sept 2017 
Chairperson  
AAPS Annual meeting 2013, San Antonio                                                                           Nov 2013 
Co-moderator  
St. John’s University -AAPS student chapter                                  Sept 2010-Aug 2011         
Treasurer                                                                                                                                             
PROFESSIONAL PRESENTATIONS 
 P.Thipsay, M.A.Repka; Effect of different HPMC grades and process parameters on physico-
chemical properties of sustained release matrix granules prepared via twin screw melt granulation  
                                                                                                                                                    Nov 2017  
 R. Lalge, P.Thipsay, M.A. Repka et.al. Cefuroxime Axetil Gastroretentive Floating Drug Delivery 
System Prepared by Hot-Melt Extrusion for Improved bioavailability                                     Nov 2017 
 P.Thipsay, M.A. Repka et al. “Formulation, evaluation and optimization of biodegradable polymeric 
implants prepared by hot-melt extrusion process” AAPS annual conference                                    Oct 2015                                           
 P.Thipsay, M.A. Repka et al. “Formulation of solid self-microemulsions using hot melt extrusion 
technology” at SPE annual technical conference, Orlando                                                                Mar 2015                                                                     
 P.Thipsay, M.A. Repka et al. “ Bioadhesive drug delivery system for enhancing bioavailability of BCS 
class III drug by hot-melt extrusion technology” at AAPS annual conference, Orlando                   Oct 2015                                
 P.Thipsay, M.A. Repka et al. “ Hot melt extrusion technology for the formulation of Solid SMEDDS” at 
AAPS annual conference, San Diego                                                                                                Nov 2014  
 P.Thipsay, E. Squillante et al. “Formulation of Ionic liquid to improve dissolution rate” at AAPS annual 




 A. Bhagurkar, P. Thipsay, M.A. Repka; Effects of formulation composition on the 
characteristics of mucoadhesive films prepared by hot-melt extrusion technology, Journal of 
Pharmacy and Pharmacology, Nov 2018 
 M. Bookwala, P.Thipsay, M.A.Repka; Preparation of a Crystalline Salt of Indomethacin and 
Tromethamine by Hot Melt Extrusion Technology, Eur. J. of Pharmaceutics and 
Biopharmaceutics, Aug 2018 
 N. Mendonsa, P. Thipsay, M.A. Repka; Bioadhesive Drug Delivery System for Enhancing the 
Permeability of a BCS Class III Drug via Hot-Melt Extrusion Technology, AAPS Pharm Sci Tech 
Feb 2017 
 A. Gandhi, B. Kirthivasan, P.Thipsay, E. Squillante; Adsorption on mesoporous silica using 
supercritical fluid technology improves dissolution rate of Carbamazepine: A poorly soluble 
compound, AAPS Pharm Sci Tech, Aug 2017. 
 
